DUOBRII (nda209354)- (0.01%;0.045%)

Generic Name	HALOBETASOL PROPIONATE; TAZAROTENE	Innovator	BAUSCH
Dosage	0.01%;0.045%
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2036-Jun-06	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	2022-Apr-25
GAIN Expiry	None	Drug Complexity	No
Indication	DUOBRII Lotion is a combination of halobetasol propionate and tazarotene indicated for the topical treatment of plaque psoriasis in adults.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	1	0

Other Developers

Total Other Developers	7

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
0.01%;0.045%	**	**	Up	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of DUOBRII